Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H1 2015

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Review, H1 2015', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Attention Deficit Hyperactivity Disorder (ADHD) Overview 8

Therapeutics Development 9

Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD)-Overview 9

Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD)-Comparative Analysis 10

Attention Deficit Hyperactivity Disorder (ADHD)-Therapeutics under Development by Companies 11

Attention Deficit Hyperactivity Disorder (ADHD)-Therapeutics under Investigation by Universities/Institutes 15

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Attention Deficit Hyperactivity Disorder (ADHD)-Products under Development by Companies 20

Attention Deficit Hyperactivity Disorder (ADHD)-Products under Investigation by Universities/Institutes 24

Attention Deficit Hyperactivity Disorder (ADHD)-Companies Involved in Therapeutics Development 25

Alcobra Ltd 25

Amarantus Bioscience Holdings, Inc. 26

Arbor Pharmaceuticals, LLC. 27

Cerecor Inc. 28

Collegium Pharmaceutical, Inc. 29

Curemark, LLC 30

DURECT Corporation 31

Eli Lilly and Company 32

H. Lundbeck A/S 33

Hisamitsu Pharmaceutical Co., Inc. 34

Integrative Research Laboratories Sweden AB 35

Intra-Cellular Therapies, Inc. 36

KemPharm, Inc. 37

Merck & Co., Inc. 38

Mnemosyne Pharmaceuticals, Inc. 39

Neos Therapeutics, Inc. 40

NeuroDerm Ltd. 41

Otsuka Holdings Co., Ltd. 42

P2D Bioscience 43

Polleo Pharma Limited 44

Reviva Pharmaceuticals Inc. 45

Samyang Biopharmaceuticals Corporation 46

Shire Plc 47

Signature Therapeutics, Inc 48

Sunovion Pharmaceuticals Inc. 49

Supernus Pharmaceuticals, Inc. 50

Taisho Pharmaceutical Co., Ltd. 51

Takeda Pharmaceutical Company Limited 52

Tris Pharma, Inc. 53

Vernalis Plc 54

Attention Deficit Hyperactivity Disorder (ADHD)-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Combination Products 56

Assessment by Target 57

Assessment by Mechanism of Action 59

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

(nicotine + opipramol hydrochloride)-Drug Profile 65

amfetamine XR-Drug Profile 66

AR-08-Drug Profile 67

BLI-1008-Drug Profile 68

BNC-375-Drug Profile 69

brexpiprazole-Drug Profile 70

centanafadine IR-Drug Profile 72

centanafadine SR-Drug Profile 73

CM-4612-Drug Profile 74

CTX-1301-Drug Profile 75

CTX-1302-Drug Profile 76

dasotraline-Drug Profile 77

dextroamphetamine-Drug Profile 79

dextroamphetamine MR-Drug Profile 80

Drug for Attention Deficit Hyperactivity Disorder-Drug Profile 81

edivoxetine-Drug Profile 82

eltoprazine-Drug Profile 84

etiguanfacine-Drug Profile 86

guanfacine hydrochloride ER-Drug Profile 87

HTL-1071-Drug Profile 89

IRL-752-Drug Profile 90

ITI-214-Drug Profile 91

KP-415 CR-Drug Profile 92

lisdexamfetamine dimesylate-Drug Profile 94

Metadoxine ER-Drug Profile 98

methylphenidate-Drug Profile 100

methylphenidate hydrochloride-Drug Profile 101

methylphenidate hydrochloride-Drug Profile 102

methylphenidate hydrochloride SR-Drug Profile 103

methylphenidate hydrochloride XR-Drug Profile 104

MGS-0028-Drug Profile 105

molindone hydrochloride ER-Drug Profile 106

PBF-509-Drug Profile 107

PD-2005-Drug Profile 109

PD-2007-Drug Profile 111

PFR-08001-Drug Profile 112

PFR-8026-Drug Profile 113

RP-5063-Drug Profile 114

SHP-465-Drug Profile 115

Small Molecule for ADHD-Drug Profile 116

Small Molecules for Attention Deficit Hyperactivity Disorder-Drug Profile 117

Small Molecules to Agonize NMDA2D for ADHD-Drug Profile 118

Small Molecules to Antagonize H3 Receptor for ADHD And Alzheimer's Disease-Drug Profile 119

Small Molecules to Inhibit COMT for Cognitive Disorders-Drug Profile 120

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 121

Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD-Drug Profile 122

Small Molecules to Modulate Choline Transporter for ADHD-Drug Profile 123

TAK-137-Drug Profile 124

TRI-102-Drug Profile 125

V-81444-Drug Profile 126

viloxazine hydrochloride-Drug Profile 127

vortioxetine hydrobromide-Drug Profile 128

Attention Deficit Hyperactivity Disorder (ADHD)-Recent Pipeline Updates 131

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects 165

Attention Deficit Hyperactivity Disorder (ADHD)-Discontinued Products 170

Attention Deficit Hyperactivity Disorder (ADHD)-Product Development Milestones 171

Featured News & Press Releases 171

Appendix 177

Methodology 177

Coverage 177

Secondary Research 177

Primary Research 177

Expert Panel Validation 177

Contact Us 177

Disclaimer 178

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015 13

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Comparative Analysis by Unknown Stage Development, H1 2015 23

Products under Development by Companies, H1 2015 24

Products under Development by Companies, H1 2015 (Contd..1) 25

Products under Development by Companies, H1 2015 (Contd..2) 26

Products under Development by Companies, H1 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Alcobra Ltd, H1 2015 29

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 30

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Arbor Pharmaceuticals, LLC., H1 2015 31

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Cerecor Inc., H1 2015 32

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Collegium Pharmaceutical, Inc., H1 2015 33

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Curemark, LLC, H1 2015 34

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by DURECT Corporation, H1 2015 35

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Eli Lilly and Company, H1 2015 36

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by H. Lundbeck A/S, H1 2015 37

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2015 38

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Integrative Research Laboratories Sweden AB, H1 2015 39

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 40

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by KemPharm, Inc., H1 2015 41

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Merck & Co., Inc., H1 2015 42

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 43

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Neos Therapeutics, Inc., H1 2015 44

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by NeuroDerm Ltd., H1 2015 45

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 46

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by P2D Bioscience, H1 2015 47

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Polleo Pharma Limited, H1 2015 48

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 49

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Samyang Biopharmaceuticals Corporation, H1 2015 50

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Shire Plc, H1 2015 51

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Signature Therapeutics, Inc, H1 2015 52

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 53

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Supernus Pharmaceuticals, Inc., H1 2015 54

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 55

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 56

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Tris Pharma, Inc., H1 2015 57

Attention Deficit Hyperactivity Disorder (ADHD)-Pipeline by Vernalis Plc, H1 2015 58

Assessment by Monotherapy Products, H1 2015 59

Assessment by Combination Products, H1 2015 60

Number of Products by Stage and Target, H1 2015 62

Number of Products by Stage and Mechanism of Action, H1 2015 64

Number of Products by Stage and Route of Administration, H1 2015 66

Number of Products by Stage and Molecule Type, H1 2015 68

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics-Recent Pipeline Updates, H1 2015 135

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects, H1 2015 169

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..1), H1 2015 170

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..2), H1 2015 171

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..3), H1 2015 172

Attention Deficit Hyperactivity Disorder (ADHD)-Dormant Projects (Contd..4), H1 2015 173

Attention Deficit Hyperactivity Disorder (ADHD)-Discontinued Products, H1 2015 174

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015 13

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 59

Number of Products by Top 10 Targets, H1 2015 61

Number of Products by Stage and Top 10 Targets, H1 2015 61

Number of Products by Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Top 10 Routes of Administration, H1 2015 65

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65

Number of Products by Top 10 Molecule Types, H1 2015 67

Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alcobra Ltd

Amarantus Bioscience Holdings, Inc.

Arbor Pharmaceuticals, LLC.

Cerecor Inc.

Collegium Pharmaceutical, Inc.

Curemark, LLC

DURECT Corporation

Eli Lilly and Company

H. Lundbeck A/S

Hisamitsu Pharmaceutical Co., Inc.

Integrative Research Laboratories Sweden AB

Intra-Cellular Therapies, Inc.

KemPharm, Inc.

Merck & Co., Inc.

Mnemosyne Pharmaceuticals, Inc.

Neos Therapeutics, Inc.

NeuroDerm Ltd.

Otsuka Holdings Co., Ltd.

P2D Bioscience

Polleo Pharma Limited

Reviva Pharmaceuticals Inc.

Samyang Biopharmaceuticals Corporation

Shire Plc

Signature Therapeutics, Inc

Sunovion Pharmaceuticals Inc.

Supernus Pharmaceuticals, Inc.

Taisho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Tris Pharma, Inc.

Vernalis Plc

ention Deficit Hyperactivity Disorder (ADHD) - Th

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutic Products under Development, Key Players in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Overview, Attention Deficit Hyperactivity Disorder (ADHD) Pipeline, Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com